- Market Capitalization, $K 252,706
- Shares Outstanding, K 217,850
- Annual Sales, $ 1,640 K
- Annual Income, $ -16,440 K
- 60-Month Beta -6.24
- Price/Sales 65.31
- Price/Cash Flow N/A
- Price/Book 2.51
|Period||Period Low||Period High||Performance|
| || |
+0.0800 (+6.96%)since 08/17/21
| || |
-0.3100 (-20.13%)since 06/17/21
| || |
-1.1200 (-47.66%)since 09/17/20
iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, announced today the appointment of...
- iBio licenses a novel antibody targeting regulatory T cells -
/PRNewswire/ -- While most of the economy has reopened, the number of new cases is once again on the rise. This time, two variants of COVID-19, the delta and lambda variants, are causing the numbers of...
The New Delta Variant Has Brought Coronavirus Into The Forefront Again. Is This Vaccine Stock 2.0?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IO, MGI, AKBA, IBIO, and XELA.
iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, today announced that preclinical studies of IBIO-202, its subunit vaccine candidate...
iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, has taken another major step towards leveraging the speed and throughput of its...
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VXRT, GRAY, JAGX, IBIO, and APTX.
iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, announced today the appointment of Evert (Eef) Schimmelpennink to its Board of...
Facts and Factors have published a new research report titled "C1 Inhibitors Market By Source (Human Derived & Recombinant Derived C1 Inhibitors), By Mode of Administration (Intravenous & Subcutaneous),...
|Etfmg Treatments Testing and Advancements ETF|
|Micro-Cap Ishares ETF|
|Principal Healthcare Innovators Index|
|Russell 2000 Value Ishares ETF|
|Mstar Small-Cap Ishares ETF|
|3rd Resistance Point||1.4067|
|2nd Resistance Point||1.3233|
|1st Resistance Point||1.2767|
|1st Support Level||1.1467|
|2nd Support Level||1.0633|
|3rd Support Level||1.0167|